CelLBxHealth has completed an oversubscribed US$10.9 million fundraise

December 2025 — CelLBxHealth has completed an oversubscribed US$10.9 million fundraise comprising a placing, subscription and retail offer.

CelLBxHealth is a specialist diagnostics company. Its proprietary Parsortix® technology can capture and harvest very rare cells, including circulating tumor cells (CTCs), from a blood sample. Parsortix has received FDA clearance for clinical use to guide precision cancer care.

Our role in the transaction

Oaklins Cavendish, one of Oaklins’ member firms in the UK, advised and supported CelLBxHealth in its fundraise. The transaction was particularly challenging given the company’s previously disclosed funding runway into the first quarter of 2026, as well as the rapid onboarding of a new management team. The new team, led by Jan Groen and Peter Collins, was delighted by the level of support from existing holders alongside substantial interest from new investors. Notably, the company raised more than twice its market capitalization, with investor demand ultimately scaled back. The strength of participation reflects investor support for the company’s strategy, its new leadership and confidence in its core technology.